These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 24431264)

  • 41. Prenatal determination of the fetal RhD blood group by multiplex PCR: a 7-year Portuguese experience.
    Pereira JC; Couceiro AB; Cunha EM; Machado AI; Tamagnini GP; Martins NP; Ribeiro ML
    Prenat Diagn; 2007 Jul; 27(7):633-7. PubMed ID: 17497744
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Noninvasive fetal RHD genotyping from maternal plasma in an admixed Brazilian population.
    Schmidt LC; Cabral AC; Faria MA; Monken F; Tarazona-Santos E; Martins ML
    Genet Mol Res; 2014 Feb; 13(1):799-805. PubMed ID: 24615044
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular determination of RHD zygosity: predicting risk of hemolytic disease of the fetus and newborn related to anti-D.
    Pirelli KJ; Pietz BC; Johnson ST; Pinder HL; Bellissimo DB
    Prenat Diagn; 2010 Dec; 30(12-13):1207-12. PubMed ID: 21072752
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Noninvasive prenatal diagnosis from maternal plasma in serological conflicts in Poland: current practice and future prospects].
    Orzińska A; Guz K; Brojer E
    Ginekol Pol; 2009 Oct; 80(10):768-71. PubMed ID: 19943542
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prenatal diagnosis of the fetal RhD blood type using a single fetal nucleated erythrocyte from maternal blood.
    Sekizawa A; Watanabe A; Kimura T; Saito H; Yanaihara T; Sato T
    Obstet Gynecol; 1996 Apr; 87(4):501-5. PubMed ID: 8602298
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A curious case of anti-D antibody titer.
    Hensley JG; Coughlin KP; Klein LL
    J Midwifery Womens Health; 2009; 54(6):497-502. PubMed ID: 19879523
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular analysis of the RhD genotype in fetuses at risk for RhD hemolytic disease.
    Spence WC; Maddalena A; Demers DB; Bick DP
    Obstet Gynecol; 1995 Feb; 85(2):296-8. PubMed ID: 7824249
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hemolytic Disease of the Fetus and Newborn: Modern Practice and Future Investigations.
    Hendrickson JE; Delaney M
    Transfus Med Rev; 2016 Oct; 30(4):159-64. PubMed ID: 27397673
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prediction of fetal blood group and platelet antigens from maternal plasma using next-generation sequencing.
    Orzińska A; Guz K; Mikula M; Kluska A; Balabas A; Ostrowski J; Uhrynowska M; Kopeć I; Dębska M; Luterek K; Brojer E
    Transfusion; 2019 Mar; 59(3):1102-1107. PubMed ID: 30620409
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [New approaches to prenatal diagnosis of rhesus incompatibility].
    Minon JM; Gérard C; Dricot JF; Neve C; Senterre JM; Schaaps JP; Foidart JM
    Rev Med Liege; 2006 Nov; 61(11):756-62. PubMed ID: 17191743
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prenatal determination of fetal blood group status.
    Avent ND; Finning KM; Martin PG; Soothill PW
    Vox Sang; 2000; 78 Suppl 2():155-62. PubMed ID: 10938946
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-invasive prenatal diagnosis and determination of fetal Rh status.
    van der Schoot CE; Hahn S; Chitty LS
    Semin Fetal Neonatal Med; 2008 Apr; 13(2):63-8. PubMed ID: 18249590
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnostic performance of the noninvasive prenatal FetoGnost RhD assay for the prediction of the fetal RhD blood group status.
    Legler TJ; Lührig S; Korschineck I; Schwartz D
    Arch Gynecol Obstet; 2021 Nov; 304(5):1191-1196. PubMed ID: 33835210
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Prevention of fetomaternal rhesus-D allo-immunization. Perspectives].
    Cortey A; Brossard Y; Beliard R; Bourel D
    J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S119-1S122. PubMed ID: 16495837
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prenatal testing for hemolytic disease of the newborn and fetal neonatal alloimmune thrombocytopenia - current status.
    Avent ND
    Expert Rev Hematol; 2014 Dec; 7(6):741-5. PubMed ID: 25374152
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-invasive fetal RHD and RHCE genotyping from maternal plasma in alloimmunized pregnancies.
    Hromadnikova I; Vesela K; Benesova B; Nekovarova K; Duskova D; Vlk R; Spalova I; Gerychova R; Hakenova A; Rosenbaumova Z; Vlasin P; Vlachova A; Palasek V; Roznakova E; Calda P
    Prenat Diagn; 2005 Dec; 25(12):1079-83. PubMed ID: 16231295
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cell-free fetal DNA in the maternal serum and plasma: current and evolving applications.
    Avent ND; Madgett TE; Maddocks DG; Soothill PW
    Curr Opin Obstet Gynecol; 2009 Apr; 21(2):175-9. PubMed ID: 19262379
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The importance of antenatal immunoprophylaxis for prevention of hemolytic disease of the fetus and newborn].
    Starcević M; Mataija M; Sović D; Dodig J; Matijević R; Kukuruzović M
    Acta Med Croatica; 2011 Mar; 65(1):49-54. PubMed ID: 21568074
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prenatal determination of fetal RhD (rhesus positive) type by an amplification of DNA.
    Kvasnicka J; Rypácková B; Calda P; Hájek Z
    Sb Lek; 1998; 99(1):13-20. PubMed ID: 9748794
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.